Stock PSTX POSEIDA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Poseida Therapeutics, Inc.

Equities

PSTX

US73730P1084

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-18 pm EDT 		5-day change 1st Jan Change
2.64 USD -6.05% Intraday chart for Poseida Therapeutics, Inc. -4.00% -21.43%
May. 14 Poseida Therapeutics Q1 Net Loss Narrows, Revenue Rises MT
May. 14 Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q1 Revenue $28.1M MT

Evolution of the average Target Price on Poseida Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

24c9fa2dd7240b563c0ffc5fc7a.GopMn9MOy_PpWus8bJlk9idxDHs4689tO2aUmDqIgE0.acIrsoZ_n5qEC65eKtERuGklei5NpaFUDi_uoAnk5S5e6XzFpkWHsLYfjA~d893b5d40b7861beec685c41d5f9a309

Analyst Recommendations on Poseida Therapeutics, Inc.

Piper Sandler Adjusts Price Target on Poseida Therapeutics to $10 From $8, Maintains Overweight Rating MT
HC Wainwright Adjusts Price Target on Poseida Therapeutics to $20 From $15, Keeps Buy Rating MT
HC Wainwright Initiates Poseida Therapeutics With Buy and $15 Price Target MT
Piper Sandler Adjusts Price Target on Poseida Therapeutics to $11 From $9, Reiterates Overweight Rating MT
Piper Sandler Adjusts Price Target on Poseida Therapeutics to $9 From $19, Maintains Overweight Rating MT
Cantor Fitzgerald Starts Poseida Therapeutics at Overweight with $24 Price Target MT
POSEIDA THERAPEUTICS : Piper Sandler Adjusts Poseida Therapeutics PT to $19 From $17, Maintains Overweight Rating MT
POSEIDA THERAPEUTICS : BTIG Initiates Poseida Therapeutics at Buy Rating With $40 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.64 USD
Average target price
14 USD
Spread / Average Target
+430.30%
High Price Target
20 USD
Spread / Highest target
+657.58%
Low Price Target
10 USD
Spread / Lowest Target
+278.79%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Poseida Therapeutics, Inc.

Piper Sandler
HC Wainwright
Cantor Fitzgerald
BTIG

Ratings for Poseida Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. PSTX Stock
  4. Consensus Poseida Therapeutics, Inc.